• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

byMichaela Dowling, MDandKiera Liblik
April 11, 2025
in Oncology, Pharma
Reading Time: 3 mins read
Breast cancer treatment collage: a woman in her 60s in a knit cardigan beside a pale blue cell with a keyhole and a brass key
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, treatment with imlunestrant significantly extended progression-free survival in those with ERS1 mutations.

2. Imlunestrant treatment was associated with lower rates of grade 3 or higher adverse events than standard therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Among breast cancer subtypes, ER-positive, HER2-negative is the most common. Treatment for this cancer targets the estrogen receptor by modulating or degrading the receptors or interfering with estrogen production. However, many cancer cells develop resistance to these treatments by acquiring mutations in the gene encoding ERα (ESR1). To enhance treatment efficacy, supplementary pharmaceuticals such as abemaciclib, a CDK4/6 inhibitor, are often used in conjunction with estrogen-targeting medications. Imlunestrant has been proposed as an estrogen receptor degrader and antagonist capable of inhibiting ESR1-mutated breast cancer. This study aimed to evaluate the efficacy of imlunestrant as monotherapy and in combination with abemaciclib in patients with advanced ER-positive, HER2-negative breast cancer. The results indicated that patients with ESR1 mutations had significantly longer progression-free survival with imlunestrant compared to standard therapy (exemestane or fulvestrant). However, when analyzing all patients, regardless of ESR1 mutation status, there was no significant difference in median progression-free survival or overall survival between the groups. The study was limited by the lack of direct comparison between fulvestrant-abemaciclib and imlunestrant-abemaciclib regimens. Nonetheless, the findings suggest that ER-positive, HER2-negative breast cancer patients experience significantly longer progression-free survival with imlunestrant—whether as monotherapy or in combination with abemaciclib—compared to current standard treatments.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

FDA approvedFor breast cancer: Etcamah (camizestrant), Sep 4, 2026→

In-Depth [randomized controlled trial]: This randomized controlled trial aimed to evaluate the efficacy of imlunestrant for the treatment of advanced ER-positive, HER2-negative breast cancer. Participants had locally confirmed advanced ER-positive, HER2-negative breast cancer, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) or non-measurable bone-only disease, and disease progression while on a CDK4/6 inhibitor, within 12 months of adjuvant treatment, or during first-line therapy. Exclusion criteria included prior treatments beyond those listed, visceral crisis, symptomatic/untreated brain metastases, or inflammatory breast cancer. Following randomization, 331 patients were assigned to the imlunestrant group, 330 to the standard therapy group, and 213 to the imlunestrant-abemaciclib group. Among patients with an ESR1 mutation, imlunestrant significantly improved median progression-free survival (5.5 months; 95% confidence interval [CI], 3.9 to 7.4) compared to standard therapy (3.8 months; 95% CI, 3.7 to 5.5; p<0.001). However, when all patients were included in the analysis, there was no significant difference observed in median progression-free survival time (hazard ratio, 0.87; 95% CI, 0.72 to 1.04; p=0.12). Overall survival was not significantly improved with imlunestrant, either in the ESR1 mutation subgroup (hazard ratio for death, 0.55; 95% CI, 0.35 to 0.86; p=0.008) or in the full cohort (hazard ratio for death, 0.69; 95% CI, 0.50 to 0.96). Treatment with imlunestrant-abemaciclib resulted in significantly longer median progression-free survival than imlunestrant monotherapy (hazard ratio for disease progression or death, 0.57; 95% CI, 0.44 to 0.73; p<0.001). However, imlunestrant-abemaciclib therapy had higher toxicity than the other treatments, with 98.1% of treated patients experiencing adverse events and 48.6% experiencing a grade three or higher adverse event. Overall, this study indicates that imlunestrant, alone or in with abemaciclib may improve progression-free survival in patients with advanced ER-positive, HER2-ngetaive breast cancer, particularly in ESR1 mutant cases.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast CancerER-positiveHER2-negativeimlunestrantoncologyPharma
Previous Post

Genomic sequencing identifies variants linked to congenital diarrhea and enteropathies

Next Post

App-based physical activity intervention may have a limited role among women with prior hypertensive pregnancy disorder

RelatedReports

A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
A middle-aged woman looks thoughtfully at an abstract representation of cells and a statin pill, symbolizing breast cancer and medication usage.
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Next Post
Blood pressure collage: a large artery cross-section ring, a tipped salt cellar spilling crystals and a plain wristwatch

App-based physical activity intervention may have a limited role among women with prior hypertensive pregnancy disorder

Exercise collage: a smiling older man with a towel over his shoulder, a kettlebell, a running shoe and a resistance band

Measuring metabolic energy expenditure for individuals with lower limb amputation

Head and neck cancer collage: a man in calm side profile, a short horizontal DNA double helix and a burnt-out match

Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.